Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a cornerstone of cancer care, particularly in metastatic non-small cell lung cancer (mNSCLC). Despite their growing impact, the mechanisms behind ADCs remain unclear for many clinicians and multidisciplinary care teams. At the same time, the expanding use of immuno-oncology (IO) therapies in mNSCLC has introduced overlapping toxicity profiles that can obscure the identification and management of ADC-related adverse events. To confidently navigate this evolving landscape, clinicians need best-in-class education that demystifies ADC mechanisms, translates clinical trial and biomarker data into actionable patient selection strategies, and differentiates safety profiles to optimize care for patients with mNSCLC.
In this Creative Educational Concepts recorded webcast, expert faculty will delineate class-wide and agent-specific characteristics of ADCs, including mechanism of action, relevant biomarkers, efficacy, toxicity profiles, and considerations for sequencing and integration of IO therapies in biomarker-selected mNSCLC. Faculty will model evidence-based interpretation of emerging clinical trial data for TROP2-directed and other ADCs to clarify their potential role across diverse mNSCLC patient populations. By strengthening clinicians’ confidence in evidence interpretation and toxicity management, this program supports more informed and individualized treatment selection for patients with mNSCLC.
Learn More Here